These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 15764962)

  • 21. Evaluation of the Patient Medication Adherence Questionnaire as a tool for self-reported adherence assessment in HIV-infected patients on antiretroviral regimens.
    Duong M; Piroth L; Grappin M; Forte F; Peytavin G; Buisson M; Chavanet P; Portier H
    HIV Clin Trials; 2001; 2(2):128-35. PubMed ID: 11590521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens.
    Horberg M; Silverberg M; Hurley L; Delorenze G; Quesenberry C
    AIDS Patient Care STDS; 2008 Apr; 22(4):301-12. PubMed ID: 18338961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of an adherence program to antiretroviral treatment on virologic response in a cohort of multitreated and poorly adherent HIV-infected patients in Spain.
    Navarro J; Pérez M; Curran A; Burgos J; Feijoo M; Torrella A; Caballero E; Ocaña I; Ribera E; Crespo M; Falcó V
    AIDS Patient Care STDS; 2014 Oct; 28(10):537-42. PubMed ID: 25111167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A simple self-reported adherence tool as a predictor of viral rebound in people with viral suppression on antiretroviral therapy.
    O'Connor JL; Gardner EM; Esser S; Mannheimer SB; Lifson AR; Telzak EE; Phillips AN;
    HIV Med; 2016 Feb; 17(2):124-32. PubMed ID: 26186609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial.
    Gibb DM; Goodall RL; Giacomet V; McGee L; Compagnucci A; Lyall H;
    Pediatr Infect Dis J; 2003 Jan; 22(1):56-62. PubMed ID: 12544410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics associated with virologic failure in high-risk HIV-positive participants with prior failure: a post hoc analysis of ACTG 5251.
    Robbins GK; Cohn SE; Harrison LJ; Smeaton L; Moran L; Rusin D; Dehlinger M; Flynn T; Lammert S; Wu AW; Safren SA; Reynolds NR
    HIV Clin Trials; 2016 Jul; 17(4):165-72. PubMed ID: 27347650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Three- or four- versus two-drug antiretroviral maintenance regimens for HIV infection.
    Rutherford GW; Sangani PR; Kennedy GE
    Cochrane Database Syst Rev; 2003; (4):CD002037. PubMed ID: 14583945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy.
    Quiros-Roldan E; Torti C; Lapadula G; Ladisa N; Micheli V; Patroni A; Cusato M; Pierotti P; Tirelli V; Uccelli MC; Di Giambenedetto S; Castelnuovo F; Gargiulo F; Manca N; Carosi G;
    AIDS Patient Care STDS; 2007 Feb; 21(2):92-9. PubMed ID: 17328658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV.
    Grossberg R; Zhang Y; Gross R
    J Clin Epidemiol; 2004 Oct; 57(10):1107-10. PubMed ID: 15528063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group.
    Haubrich RH; Little SJ; Currier JS; Forthal DN; Kemper CA; Beall GN; Johnson D; Dubé MP; Hwang JY; McCutchan JA
    AIDS; 1999 Jun; 13(9):1099-107. PubMed ID: 10397541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.
    Dybul M; Fauci AS; Bartlett JG; Kaplan JE; Pau AK;
    Ann Intern Med; 2002 Sep; 137(5 Pt 2):381-433. PubMed ID: 12617573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine.
    Campo RE; Da Silva BA; Cotte L; Gathe JC; Gazzard B; Hicks CB; Klein CE; Chiu YL; King MS; Bernstein BM
    AIDS Res Hum Retroviruses; 2009 Mar; 25(3):269-75. PubMed ID: 19292590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease.
    Eldred LJ; Wu AW; Chaisson RE; Moore RD
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jun; 18(2):117-25. PubMed ID: 9637576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection.
    Ammassari A; Murri R; Pezzotti P; Trotta MP; Ravasio L; De Longis P; Lo Caputo S; Narciso P; Pauluzzi S; Carosi G; Nappa S; Piano P; Izzo CM; Lichtner M; Rezza G; Monforte A; Ippolito G; d'Arminio Moroni M; Wu AW; Antinori A;
    J Acquir Immune Defic Syndr; 2001 Dec; 28(5):445-9. PubMed ID: 11744832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania.
    Ramadhani HO; Thielman NM; Landman KZ; Ndosi EM; Gao F; Kirchherr JL; Shah R; Shao HJ; Morpeth SC; McNeill JD; Shao JF; Bartlett JA; Crump JA
    Clin Infect Dis; 2007 Dec; 45(11):1492-8. PubMed ID: 17990233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A meta-analysis of adherence to antiretroviral therapy and virologic responses in HIV-infected children, adolescents, and young adults.
    Kahana SY; Rohan J; Allison S; Frazier TW; Drotar D
    AIDS Behav; 2013 Jan; 17(1):41-60. PubMed ID: 22411426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.
    Dybul M; Fauci AS; Bartlett JG; Kaplan JE; Pau AK;
    MMWR Recomm Rep; 2002 May; 51(RR-7):1-55. PubMed ID: 12027060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine.
    Cahn P; Vibhagool A; Schechter M; Soto-Ramirez L; Carosi G; Smaill F; Jordan JC; Pharo CE; Thomas NE; Steel HM
    Curr Med Res Opin; 2004 Jul; 20(7):1115-23. PubMed ID: 15265256
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis.
    Mills EJ; Nachega JB; Buchan I; Orbinski J; Attaran A; Singh S; Rachlis B; Wu P; Cooper C; Thabane L; Wilson K; Guyatt GH; Bangsberg DR
    JAMA; 2006 Aug; 296(6):679-90. PubMed ID: 16896111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lamivudine Concentration in Hair and Prediction of Virologic Failure and Drug Resistance among HIV Patients Receiving Free ART in China.
    Yan J; Liu J; Su B; Pan X; Wang Z; Wu J; Zhang J; Ruan Y; Hsi J; Liao L; Shao Y; Xing H
    PLoS One; 2016; 11(4):e0154421. PubMed ID: 27119346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.